1 / 45

RECENT INNOVATIONS IN STERILE DOSAGE FORMS

RECENT INNOVATIONS IN STERILE DOSAGE FORMS. Content . What are sterile dosage forms. Types of Conventional Sterile dosage forms. What is the need to develop an innovative sterile dosage forms. Types of sterile dosage form, 4.1 Ophthalmic. 4.2 Intranasal & Pulmonary Drug Delivery.

maddy
Télécharger la présentation

RECENT INNOVATIONS IN STERILE DOSAGE FORMS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RECENT INNOVATIONS INSTERILE DOSAGE FORMS

  2. Content • What are sterile dosage forms. • Types of Conventional Sterile dosage forms. • What is the need to develop an innovative sterile dosage forms. • Types of sterile dosage form, 4.1 Ophthalmic. 4.2 Intranasal & Pulmonary Drug Delivery. 4.3 Implants. 4.4 Parenteral. 4.5 Others. • References 2/ 45

  3. 1. What are sterile dosage forms • A dosage form is said to be sterile when it is free from, • Microrganism, • Pathogens and • Spores • In short must be free from all types of Microbial contamination. • Sterile products are mostly injected, applied onto eye and administer intranasally. 3/45

  4. 4 / 45

  5. 5 / 45

  6. 4.1 Ophthalmic 4.1.1 Ophthalmic Insitu gels 4.1.2 Ophthalmic Cationic emulsion 4.1.3 Ophthalmic Iontophoresis 4.1.4 Ophthalmic Nanoparticle 4.1.5 Ophthalmic Discosomes 4.1.6 Ocular Inserts 6 / 45

  7. 4.1.1 Ophthalmic Insitu gels • These type of systems can be formulated as drug-containing liquids suitable for administration by instillation into the eye, which upon exposure to physiological conditions will shift to the gel (semi-solid) phase, thus increasing the precorneal residence time and enhancing the ocular bioavailability of the drug. • Mechanism by which Insitu gels are being formed in eye are, • Temperature Dependent System • pH dependent system • Ion Induced System 7/ 45

  8. 4.1.2 Ophthalmic Cationic emulsion • They are developed by the Novagali pharmaceuticals for ophthalmic applications in retina via the trans-scleral route • Electrostatic attraction that occurs between positively charge droplets and negatively charged cell membranes. • Administration onto the eye has shown, increase the residence time of the drug at cornea, with a lower contact angle and an increased spreading coefficient in comparison with conventional eye drops and anionic emulsions. 8 / 45

  9. 4.1.3 Ophthalmic Iontophoresis • Iontophoresis is an active method of drug delivery which uses a small electrical currentto transport ionized drugs into and through body tissues. • The results of studies in rabbit, demonstrate that iontophoresis offers a noninvasive and reproducible means of delivering a model anionic drug to eye tissues, specifically to the retina. • These studies serve as the basis for future clinical studies aimed at delivering therapeutic drugs to the back of the eyefor treatmentof ocular diseases, such as Age-related macular degeneration (AMD) and diabetic retinopathy (DR). 9 / 45

  10. 4.1.4 Ophthalmic Nanoparticle 10 / 45

  11. 4.1.5 Ophthalmic Discosomes • Disc shaped niosomes are known as discosomes. • Discosomes, in addition to their many advantages, seem to have a special advantage towards the ocular route, wherein their large size may prevent their drainage into the systemic pool. • Furthermore, their ‘‘disc’’ shape provides for a better fit in the cul-de-sac of the eye. • Non-ionic surfactant-based discoidal noisome (discosomes) of timolol maleate have been reported to be promising systems for the controlled ocular administration of water-soluble drugs, releasing the drug in a biphasic profile. 11 / 45

  12. 4.1.6 Ocular Inserts • A truly continuous Zero order kinetic & controlled release was achieved using ocusert. • Pilocarpine ocuserts ( by Alza corporation of California) i.e. pilo- 20 & pilo- 40 are examples • This device is more popular among younger patients as compared to elder population who have difficulties in insertion, do not retain device well and often do not notice if it falls out. • The major drawback for using this therapy is • high cost of the device • this system is not biodegradable, • required to be removed and replaced with a fresh one. • They also include soluble, bioadhesive ophthalmic inserts, prosert and mydriasert. 12/ 45

  13. 13 / 45

  14. 4.2 Pulmonary Drug Delivery 4.2.1 Liposome and Lipid Based Formulation 4.2.2 Proliposomes 4.2.3 Nanocochleates 4.2.4 Micro and Nanoparticulates DPI Compositions 4.2.5 Delivery of Proteins, Peptides and Macromolecules for Local and Systemic Delivery Using DPIs 4.2.6 Matrix formation 4.2.7 pro-drugs and pegylation 14 / 45

  15. 4.2.1 Liposome and Lipid Based Formulation • Promising in sustaining the drug residence time within lung, improving therapeutic index, and delaying systemic dilution and thereby, reducing side effects and to control the extent of release. • Delivery of corticosteroid for asthma, ribonucleotides for respiratory influenza aminoglycosides (Tobramycin Sulphate, Amikacin Sulphate) and other antibiotics (Ciprofloxacin) for local pulmonary infections and cystic fibrosis has been reported using liposome technology. • In liposomal DPI formulations, drug encapsulated liposomes are homogenized, dispersed into carrier and converted into DPI by spray and / or freeze drying. • On inhalation, drug encapsulated liposome’s get rehydratedin lung and release drug over a period of time. • Fatty acid esters were incorporated in the lipid portion of liposome’s for prolonged steroid retention in the respiratory tract. 15 / 45

  16. 4.2.2 Proliposomes • Biologically active component with a lipid or mixture having a phase transition temperature of below 37°C for inhalation has been described for manufacturing of proliposomes. • A DPI formulation comprising a lipid component and an active agent having a liquid phase transition temperature of less than or equal to 37°C on hydration and a liquid phase transition temperature of greater than 57°C in dry form. • On inhalation the drug spontaneously encapsulatesinto lipid inside lungs. The disclosed formulation is useful in treatment of anthrax infection on inhalation. 16 / 45

  17. 4.2.3 Nanocochleates • Cochleates are derived from liposomes. • These are suspended in an aqueous containing two-phase polymer solution, perceiving different partition coefficient. • The liposome containing two-phase polymer solution, treated withpositively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than 1 µm. • Novel lipid-based cochleate delivery system were used to achieve efficient systemic and mucosal delivery of pharmaceutical agents. 17 / 45

  18. 4.2.4 Micro and Nanoparticulates DPI Compositions • Respirable particles carrying active principles or diagnostics in nanoparticle • Nanoparticulates DPI produced by mixing the nanoparticles with liquid carrier, then forming the resultant mixture into respirable particles. • The respirable particles were produced by spray-drying or freeze spray dryingfollowed by comminution, for delivery to the lungs via DPIs. • Active principles were covalently attached, adsorbed or incorporated to nanoparticles. 18 / 45

  19. 4.2.5 Delivery of Proteins, Peptides and Macromolecules for Local and Systemic Delivery Using DPIs • It has been found that inhaled dry insulin powders are deposited in the alveolar regions of the lungs and rapidly absorbed through the epithelial cells of the alveolar region into blood circulation. • The insulin powder preferably comprises particles having a diameter range from 0.1 µm to 5 µm. • A patent on pulmonary malarial vaccine relates to particulate compositions comprising nanoparticulates for pulmonary delivery, which provide sustained release of antigens, preferably DNA and/or peptide and/or protein antigens has been developed. • As the aggregate particles degrade in the body, MSP-1 and AMA-1 proteins are released into the blood stimulating a humoural immune response. • The individual particles in the range of 0.1 micron are referentially phagocytosed & initiating the cellular immune response that is necessary for a complete immunity. 19 / 45

  20. 20/ 45

  21. 4.3 Implants • Implants are defined as sterile solid drug products made by compression, melting, or sintering. They generally consist of the drug and rate-controlling excipient. 4.3.1 Implantable Osmotic Pumps 4.3.2 Vapor pressure moderated implantable device 4.3.3 Biodegradable device 4.3.4 Ophthalmic implant 21 / 45

  22. 4.3.1 Implantable Osmotic Pumps 22 / 45

  23. opening Drug and Polymer Collapsible bag Propellant 4.3.2 Vapor Pressure Moderated Implantable Devices 23/ 45

  24. 4.3.3 Biodegradable device • Example of Biodegradable device is ZOLADEX (Goserelin Acetate Implant) • Zoladex is a sterile, biodegradable product containing goserelin acetate designed for subcutaneous injection continuous release over 28 days. • Zoladex is also availble as Zoladex- 3 month. The base consists of a matrix of D, L- lactic and glycolic acid copolymer. • Zoladex is indicated for a number of disorders, including palliative treatment of advanced carcinoma of the prostate. It is also used in treatment of advanced breast cancer. 24 / 45

  25. Cont… • Another Example of Biodegradable device is Gliadel Wafer Implant • Gliadel Wafer (polifeprosan 20 with carmustine implant) is indicated in newly diagnosed patients with high-grade malignant as an adjunct to surgery and radiation. • After a neurosurgeon removes a high-grade malignant, up to eight Gliadel Wafers can be implanted in the cavity where the tumor resided. • Once implanted, the Gliadel Wafers slowly dissolve, releasing high concentrations of BCNU into the tumor site targeting microscopic tumor cells that sometimes remain after surgery. • The specificity of Gliadel Wafer minimizes drug exposure to other areas of the body. 25 / 45

  26. 4.3.4 Ophthalmic implant LACRISERT • A rod shaped pellet of Hydroxypropyl Cellulose without preservative • This device is designed as a sustained release artificial tear insert for the treatment of dry eye disorders VITRASERT • Effective in treating cytomegalovirus (CMV) retinitis. • This implant delivers the drug directly to the retina for over 5 months. • The device was prepared by coating a ganciclovir pellet with PVA. 26 / 45

  27. 4.4 Parenteral 4.4.1 Liposome Parenteral Formulation 4.4.2 Depofoam 4.4.3Microsphere 4.4.4 Noisome 4.4.5 Nanosuspension 4.4.6 Others 27 / 45

  28. 4.4.1 Liposome Parenteral Formulation • AmBisome is amphotericin B liposome for injection. • It is a sterile, nonpyrogenic lyophilized product for intravenous infusion. • Intravenous infusion forms upon reconstituted with sterile water for injection. • AmBisome is a true single bilayer liposomal drug delivery system, consisting of unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. 28/ 45

  29. DaunoXome DaunoXome (daunorubicin citrate liposome injection) is a sterile, pyrogen-free, preservative-free product in a single use vial for intravenous infusion. DaunoXome is a liposomal preparation of daunorubicin formulated to maximize the selectivity of daunorubicin for solid tumors in situ. Doxil Doxil (doxorubicin HCl liposome injection) is doxorubicin hydrochloride (HCl) encapsulated in STEALTH® liposomes for intravenous administration. The STEALTH liposomes of Doxilare formulated with surface-bound methoxypolyethylene glycol (MPEG), a process often referred to as pegylation, to protect liposomes from detection by the mononuclear phagocyte system (MPS) and to increase blood circulation time. Cont… 29 / 45

  30. 4.4.2 Depofoam • DepoFoam® is a non-classical liposome technology designed for sustained release of therapeutic agents following injection into sites other than the bloodstream. • Unlike classical liposomes, where the lipid bilayers are in concentric shells, each MLV particle is a honeycomb of numerous non-concentric aqueous chambers surrounded by lipid bilayers. 30 / 45

  31. DepoDur There is widespread recognition that relief of post-operative pain is sub-optimal. In DepoDur™ (previously known as DepoMorphine™), our DepoFoam™ sustained-release injectable technology maintains therapeutically effective levels of morphine for 48 hours (the period of peak post-operative pain) from a single epidural injection given before or during the procedure. DepoDur™ eliminates the need for an indwelling catheter and infusion pumps. DepoCyt DepoCyt is first sustained-release injectable product to reach the market which uses DepoFoam technology. DepoCyt cuts the injection frequency to every second week, allowing treatment on an outpatient. DepoCyt® was launched in the USA in May 1999. Cont… 31 / 45

  32. 4.4.3 Microsphere • The Biosphere® drug delivery system consists of microspheres of highly purified starch forming a matrix in which the drug is encapsulated by using a proprietary and gentle process without exposure to organic solvents, high shear forces or extremes of pH. • The Biosphere® drug delivery system offers: • Gentle manufacturing process, preserving protein integrity and stability • Biocompatible and biodegradable materials • Good control of properties providing long-term release profiles • Injections via small needles or needle-less systems • High encapsulation efficiency, minimising loss of costly drug substance 32 / 45

  33. 4.4.4 Niosome • The success achieved with liposomes stimulated the search for other vesicle forming amphiphiles which led to the development of Niosomes. • Non-ionic surfactants were among the first alternative materials studied. • Drug targeting of anticancer drugs like methotrexate and doxorubicin has been achieved by niosomal formulations. 33 / 45

  34. 4.4.5 Nanosuspension 34 / 45

  35. 35/ 45

  36. 4.4.6 Others • Transferosomes: Modified liposomes developed to increase the transdermal permeation of drug. Deformability is achieved by using surface active agent in proper ratio. • Ethosome: Ethosomal system is a vesicular system composed mainly of phospholipids & alcohol (ethanol or IPA, sometimes polyols; glycol) in relatively high concentration & water. Better membrane permeability. • Discosomes • Virosomes:Reconstituted lipid vesicles equipped with viral glycoprotein is used for DNA transfer. • Emulsomes: The emulsomes can be explicitly distinguished from fat emulsion or lipid microsphere as they are distinctively sphere vesicular graft like system due to utilization of higher quantities of PC both as emulsifying agent as well as surface modifier. • Cochleates: Cochleates are cigar-like microstructures that consist of a series of lipid bilayers which are formed as a result of the condensation of small unilamellar negatively charged liposomes. In the presence of calcium, the small phosphatidylserine (PS) liposomes fuse and form large sheets. These sheets have hydrophobic surfaces and, in order to minimize their interactions with water, tend to roll-up into the cigar-like cochleate. 36 / 45

  37. 37 / 45

  38. 4.5. Others 4.5.1 Prefilled-Syringe 4.5.2 Pens 4.5.3 Auto injector 4.5.4 Infusion Pump 4.5.5 Ultrasafe Passive Delivery System 38 / 45

  39. 4.5.1 Prefilled-Syringe • Duoject - Prefillable Syringe Systems And Lyophilized Drug Reconstitution Devices: its work on the advancement of parenteral technology, developing medical devices for pharmaceutical clients which meet patient needs for safety, precision and simple ease of use in drug reconstitution and delivery • Vari-vial™ Prefillable Syringe: Vari-Vial™ - a prefillable syringe and novel bottomless vial capable of being processed on standard 'in-house or outsourced' vial production machinery. 39 / 45

  40. 4.5.2 Pens • Insulin Pens: Insulin pen is the combination of the syringe and insulin cartridge into one. • It has made multiple insulin injections more convenient, portable and acceptable. • Disposable And Semi-disposable Injection Pens: Patented disposable 'dose memory' pens and 'click-on' pen needles make giving injections more convenient 40 / 45

  41. 4.5.3 Auto injector • EpiPen and EpiPen autoinjectors: Epipen autoinjectors are designed as emergency supportive therapy for allergenic reactions (anaphylaxis) and are not a replacement or substitute for immediate medical or hospital care. • Disposable And Reusable Auto-injectors: Disposable and reusable auto-injector platforms provide safe and easy injections from pre-filled syringes. • PEN INJECTORS - TYPICAL DOSING RANGE 0.01ML-0.8ML Pen injectors are typically multi-dose injectors used mainly for frequent injections. Injection pens are used with dedicated drug cartridges and pen needles. • REUSABLE INJECTION PENS Ypsomed reusable injection pens are available with easy to read electronicdisplays for multiple dosing with optimal accuracy. 41 / 45

  42. 4.5.4 Infusion Pump • Insulin Pumps: The insulin pump is a small portable device (about the size and weight of a pager) that delivers insulin continuously through a fine plastic tubeinto a site under the skin. Users will need to go through a comprehensive training. • The insulin pump generally gives you better control and more meal flexibility but is costly and still requires frequent blood sugar monitoring. • The catheter at the end of the insulin pump is inserted through a needle into the abdominal fat of a person with diabetes. • Dosage instructions are entered into the pump's small computer and the appropriate amount of insulin is then injected into the body in a calculated, controlled manner. 42 / 45

  43. Cont… • Infusion Pumps: COLLEAGUE CX Infusion Pump with GUARDIAN Feature. From simple infusions to medication therapies requiring complex dose calculations. • GUARDIAN feature to help reduce medication errors by alerting staff when programmed doses are not met within institutional limits • PCA II Pump Innovative in Pain Management: The convenience of safe and precise Patient Controlled Analgesia in a flexible system designed with advanced technology. This is progressive, innovative, and effective pain management in a sophisticated, yet simple-to-operate, instrument. • FLO-GARD 6201 Volumetric Infusion Pump and the FLO-GARD 6301 Dual-Channel Volumetric Infusion Pump:Flow Check Occlusion Alarm offers an in-line resistancedisplay of incremental back pressure. Flow Rate Calculation is automatic after volume and time are selected. 43 / 45

  44. 4.5.5 Ultrasafe Passive Delivery System • The UltraSafe® Passive™ Delivery System offers a complete pharmaceutical delivery system as well as an effective solution for protecting workers from the horror of needlesticks. • Specifically designed for pre-filled glass syringes, the UltraSafe® Passive™ Delivery System leaves nothing to change. With innovative passive protection that delivers the ultimate in sharps injury protection and safety, it provides a complete delivery system with no change in current technique. • UltraSafe®needle guards are designed to attach easily to most pre-filled glass syringes commonly used with vaccines,low molecular weight heparins and many new biotechnology drugs. 44/ 45

  45. 5. References • http://www.pharmaceutical-technology .com/contractors/drug_delivery/crossject/ • http://www.pharmaceutical-technology.com/contractors/drug_delivery/syringes/ • http://www.ondrugdelivery.com/publications/Pre-Injectables%20lo%20res.pdf • http://www.pharmainfo.net/exclusive/reviews/advances_in_ophthalmic_drug_delivery_systems_-_part_ii./ • http://www.pharmainfo.net/exclusive/reviews/advances_in_ophthalmic_drug_delivery_systems_:_part_i/ • http://www.azonano.com/Details.asp?ArticleID=1538 • http://www.amphastar.com/products.htm • http://www.drugs.com/PDR/Pulmicort_Respules.html • http://www.astrazeneca-us.com/pi/pulmicortrespules.pdf • http://wistechnology.com/article.php?id=1186 • http://www.freedommedical.com/hosp.asp?mode=sel&pid=00024&intpage=2&action=<< • http://www.ioltech.com/beta/uk/pharma.html • http://www.surgical-net-tv.com/lab-ioltech.cfm • http://www.insitevision.com/wt/page/index • http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15547470&dopt=Abstract • http://www.advantagerx.com/dispins.htm • http://www.run500miles.com/insulin_pumps.htm • http://www.nipro.co.jp/english/profile/labo.html • http://www.gilead.com/wt/sec/liposomal_technology • http://www.ambisome.com/ • http://www.drugs.com/PDR/Doxil_Injection.html • http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=62 • http://www.pjonline.com/Editorial/19990904/education/parenteral2.html • http://www.nlm.nih.gov/medlineplus/ency/imagepages/18035.htm • http://www.pjbpubs.com/uploads/drugdelivery.pdf • Ansel’s Pharmaceutical Dosage Forms and Drug delivery Systems. Eighth edition. Novel Dosage Forms and Drug Delivery Technologies: 652-672. 45 / 45

More Related